Q2 2026 saw improved sales and EBITDA margin, driven by a recovering 300 mm market and successful capital increase. Guidance for 2026 sales was slightly raised, with gradual recovery expected, though pricing and product mix remain challenges.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.